Similar articles for PMID: 31399316

Year	Number of Results
1997	2
1998	1
2004	1
2005	2
2006	1
2007	6
2008	3
2009	2
2010	3
2012	4
2013	5
2014	13
2015	12
2016	19
2017	8
2018	6
2019	4
2020	4
2021	2
2022	1
2023	2
2024	0

1

Corrigendum to "Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients". [Int J Antimicrob Agents 51 (2018) 594-600].

Dhaese SAM, Roberts JA, Carlier M, Verstraete AG, Stove V, De Waele JJ. Dhaese SAM, et al. Int J Antimicrob Agents. 2019 Sep;54(3):380. doi: 10.1016/j.ijantimicag.2019.07.022. Epub 2019 Aug 6. Int J Antimicrob Agents. 2019. PMID: 31399316 No abstract available.

2

Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients.

Dhaese SAM, Roberts JA, Carlier M, Verstraete AG, Stove V, De Waele JJ. Dhaese SAM, et al. Int J Antimicrob Agents. 2018 Apr;51(4):594-600. doi: 10.1016/j.ijantimicag.2017.12.015. Epub 2017 Dec 22. Int J Antimicrob Agents. 2018. PMID: 29277531

3

Corrigendum to 'Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients' [International Journal of Antimicrobial Agents 51 (2018) 594-600].

Dhaese SAM, Roberts JA, Carlier M, Verstraete AG, Stove V, DeWaele JJ. Dhaese SAM, et al. Int J Antimicrob Agents. 2019 Aug;54(2):271. doi: 10.1016/j.ijantimicag.2019.07.007. Epub 2019 Jul 8. Int J Antimicrob Agents. 2019. PMID: 31296408 No abstract available.

4

First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.

Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. Roberts JA, et al. Int J Antimicrob Agents. 2010 Feb;35(2):156-63. doi: 10.1016/j.ijantimicag.2009.10.008. Epub 2009 Dec 16. Int J Antimicrob Agents. 2010. PMID: 20018492

5

Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT.

Shotwell MS, Nesbitt R, Madonia PN, Gould ER, Connor MJ, Salem C, Aduroja OA, Amde M, Groszek JJ, Wei P, Taylor ME, Tolwani AJ, Fissell WH. Shotwell MS, et al. Clin J Am Soc Nephrol. 2016 Aug 8;11(8):1377-1383. doi: 10.2215/CJN.10260915. Epub 2016 May 19. Clin J Am Soc Nephrol. 2016. PMID: 27197907 Free PMC article.

6

Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration.

Jamal JA, Roberts DM, Udy AA, Mat-Nor MB, Mohamad-Nor FS, Wallis SC, Lipman J, Roberts JA. Jamal JA, et al. Int J Antimicrob Agents. 2015 Jul;46(1):39-44. doi: 10.1016/j.ijantimicag.2015.02.014. Epub 2015 Mar 28. Int J Antimicrob Agents. 2015. PMID: 25881872 Clinical Trial.

7

Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?

Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Roberts JA, et al. Crit Care Med. 2009 Mar;37(3):926-33. doi: 10.1097/CCM.0b013e3181968e44. Crit Care Med. 2009. PMID: 19237898 Clinical Trial.

8

Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.

Awissi DK, Beauchamp A, Hébert E, Lavigne V, Munoz DL, Lebrun G, Savoie M, Fagnan M, Amyot J, Tétreault N, Robitaille R, Varin F, Lavallée C, Pichette V, Leblanc M. Awissi DK, et al. Pharmacotherapy. 2015 Jun;35(6):600-7. doi: 10.1002/phar.1604. Pharmacotherapy. 2015. PMID: 26095008

9

Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.

Asín-Prieto E, Rodríguez-Gascón A, Trocóniz IF, Soraluce A, Maynar J, Sánchez-Izquierdo JÁ, Isla A. Asín-Prieto E, et al. J Antimicrob Chemother. 2014 Jan;69(1):180-9. doi: 10.1093/jac/dkt304. Epub 2013 Aug 1. J Antimicrob Chemother. 2014. PMID: 23908259 Clinical Trial.

10

Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.

Roger C, Cotta MO, Muller L, Wallis SC, Lipman J, Lefrant JY, Roberts JA. Roger C, et al. Int J Antimicrob Agents. 2017 Aug;50(2):227-231. doi: 10.1016/j.ijantimicag.2017.03.018. Epub 2017 Jul 6. Int J Antimicrob Agents. 2017. PMID: 28689876

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

86 results

Results by year